OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
25
Results
Show all
Save search
Copy query
Show results for
Unknown
(25)
Publication Date
Release Date
2021
(10)
2023
(5)
2022
(5)
2025
(3)
2020
(1)
2018
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries.
Not available
S-EPMC10364528
|
biostudies-literature
Cite
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Not available
S-EPMC7953461
|
biostudies-literature
Cite
Simvastatin in Critically Ill Patients with Covid-19.
Not available
S-EPMC10755839
|
biostudies-literature
Cite
Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA.
Not available
S-EPMC5920066
|
biostudies-literature
Cite
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Not available
S-EPMC8274471
|
biostudies-literature
Cite
Dexamethasone in Hospitalized Patients with Covid-19.
Not available
S-EPMC7383595
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594
|
biostudies-literature
Cite
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338
|
biostudies-literature
Cite
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets